CLINICAL TRIALS PROFILE FOR MIRTAZAPINE

All Clinical Trials for MIRTAZAPINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00021528 ↗	Sequenced Treatment Alternatives to Relieve Depression (STAR*D)	Completed	National Institute of Mental Health (NIMH)	Phase 4	2001-07-01	STAR*D focuses on non-psychotic major depressive disorder in adults who are seen in outpatient settings. The primary purpose of this research study is to determine which treatments work best if the first treatment with medication does not produce an acceptable response. Participants will first receive citalopram, an SSRI medication; if symptoms remain after 8-12 weeks of treatment, up to four other levels of treatment will be offered, including cognitive therapy and other medications. There are no placebo treatments. Some patients may require a combination of two or more treatments to obtain full benefit. Participation could last from 15 to 27 months and involve up to 30 clinic visits. Participants will be interviewed by telephone throughout the study about their symptoms, daily functioning, treatment side effects, use of the health care system, and satisfaction with treatment. There will be a one-year follow up for participants once their depression has been successfully treated
NCT00080158 ↗	Treatment of Adolescent Suicide Attempters (TASA)	Completed	National Institute of Mental Health (NIMH)	Phase 2/Phase 3	2004-03-01	The purpose of this study is to compare the effects of three types of treatments for depressed teenagers who have attempted suicide.
NCT00080158 ↗	Treatment of Adolescent Suicide Attempters (TASA)	Completed	New York State Psychiatric Institute	Phase 2/Phase 3	2004-03-01	The purpose of this study is to compare the effects of three types of treatments for depressed teenagers who have attempted suicide.
NCT00108498 ↗	New Pharmacological Treatment for Obstructive Sleep Apnea	Completed	US Department of Veterans Affairs	Phase 1	2003-10-01	This study will determine if mirtazapine, a unique antidepressant that does not disturb sleep, will improve obstructive sleep apnea (OSA). The design is randomized, crossover, double blind, and placebo controlled. On two consecutive nights of one week, the patients receive either 30 mg mirtazapine or placebo at bedtime. The following week, the alternative medication is administered. The patients have known mild to moderate sleep apnea. The endpoints of the study are the apnea + hypopnea index (AHI), sleep quality, and the degree of arterial oxygen desaturation.
NCT00108498 ↗	New Pharmacological Treatment for Obstructive Sleep Apnea	Completed	VA Office of Research and Development	Phase 1	2003-10-01	This study will determine if mirtazapine, a unique antidepressant that does not disturb sleep, will improve obstructive sleep apnea (OSA). The design is randomized, crossover, double blind, and placebo controlled. On two consecutive nights of one week, the patients receive either 30 mg mirtazapine or placebo at bedtime. The following week, the alternative medication is administered. The patients have known mild to moderate sleep apnea. The endpoints of the study are the apnea + hypopnea index (AHI), sleep quality, and the degree of arterial oxygen desaturation.
NCT00150839 ↗	Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy	Completed	University of Erlangen-Nürnberg	Phase 4	2006-03-01	The proposed study is a randomized, placebo-controlled, double-blind trial to evaluate the safety and efficacy of antidepressant combination for the treatment of depression. Depressive disorder is one of the most common human diseases with a high burden for every patient, her/his family, health care system and society as a whole. Actual treatment concepts of depressive disorders include pharmacologic, biologic (e.g. electroconvulsive therapy, light therapy) and psychologic therapy. Even though effective therapeutic options are at hand, therapy needs time. It is often not possible to reach full remission of the disease and 10-25% of patients suffering from depression are regarded as "treatment-resistant". In treatment resistant depression, the use of a combination of antidepressive drugs is considered safe and effective. However, at present no data exist concerning the use of drug combination as primary therapeutic option. The aim of the study is to examine the hypothesis, that significantly more patients achieve full remission of depressive symptoms when treated with the combination of two antidepressants and as a secondary hypothesis, that patients receiving a drug combination will achieve remission faster than patients treated with monotherapy. To test these hypotheses, a two group parallel design is used comparing the efficacy and safety of mirtazapine in combination with venlafaxine or placebo.

Clinical Trial Conditions for MIRTAZAPINE

Condition Name

Condition Name for MIRTAZAPINE
Intervention	Trials
Depression	14
Major Depressive Disorder	13
Healthy	8
Anorexia	6

Condition MeSH

Condition MeSH for MIRTAZAPINE
Intervention	Trials
Depression	36
Depressive Disorder	27
Depressive Disorder, Major	21
Disease	15

Clinical Trial Locations for MIRTAZAPINE

Trials by Country

Trials by Country for MIRTAZAPINE
Location	Trials
United States	113
China	12
Egypt	7
Germany	6
United Kingdom	5

Trials by US State

Trials by US State for MIRTAZAPINE
Location	Trials
Texas	9
North Carolina	8
New York	8
California	8
Pennsylvania	8

Clinical Trial Progress for MIRTAZAPINE

Clinical Trial Phase

Clinical Trial Phase for MIRTAZAPINE
Clinical Trial Phase	Trials
PHASE4	1
PHASE2	4
PHASE1	1

Clinical Trial Status

Clinical Trial Status for MIRTAZAPINE
Clinical Trial Phase	Trials
COMPLETED	59
Recruiting	18
Unknown status	11

Clinical Trial Sponsors for MIRTAZAPINE

Sponsor Name

Sponsor Name for MIRTAZAPINE
Sponsor	Trials
National Institute of Mental Health (NIMH)	5
Ain Shams University	5
National Institute on Drug Abuse (NIDA)	5

Sponsor Type

Sponsor Type for MIRTAZAPINE
Sponsor	Trials
Other	154
Industry	20
NIH	15

MirtaZapine: Clinical Trial Update, Market Analysis and Projections

Last updated: April 25, 2026

What is mirtazapine’s current clinical trial landscape?

Mirtazapine is an established antidepressant with a long clinical record and ongoing, but mostly incremental, evidence generation (new formulations, indications, and comparative or safety studies rather than first-in-class development). As of the latest publicly indexed listings, the dominant pattern across registries is investigator-initiated or sponsor-sponsored studies that focus on:

• Treatment optimization (dose timing, titration strategy, and response tracking)
• Comparative effectiveness versus other antidepressants or adjunct strategies
• Safety and tolerability assessments in specific populations
• Special populations and settings (e.g., geriatric, comorbidities, psychiatric-physical care pathways)

Implication for investors and R&D: the current clinical activity profile for mirtazapine is consistent with a mature asset where new value creation typically comes from line extensions, formulation IP, route-of-administration, and payer-relevant outcomes rather than a brand-new mechanism.

Where does mirtazapine sit in the trial pipeline by phase?

Publicly indexed trials generally skew toward late-stage observational/real-world studies and Phase 4-type evaluations, with far fewer interventional Phase 2/3 programs than in newer antidepressant classes.

A practical way to interpret the landscape:

• Phase 1: limited activity given known pharmacology
• Phase 2/3: periodic comparator studies and strategy trials, often smaller and region-specific
• Phase 4/observational: persistent activity across geographies, frequently used for safety, adherence, and comparative effectiveness evidence

Market impact: Phase 4 evidence is heavily weighted by payers and health technology assessment bodies for coverage decisions and preferred formulary placement, especially where cost and discontinuation rates are decision drivers.

Which clinical readouts typically move the market for mirtazapine?

When mirtazapine is studied today, the endpoints most often used to support differentiation are:

• Response rate and time-to-response (HAM-D or MADRS-based measures)
• Remission rates at fixed timepoints (commonly 6 to 8 weeks in depression trials)
• Discontinuation due to adverse events
• Weight gain and metabolic tolerability signals
• Sedation-related outcomes (daytime impairment)
• Elderly tolerability and falls-related safety proxies
• Comorbidity outcomes in real-world cohorts

Implication: real-world effectiveness and tolerability in routine practice matter more for mirtazapine-like assets than novel mechanistic claims.

---

What is the market size for mirtazapine and how is it evolving?

Mirtazapine is widely available globally as a generic antidepressant, with brand-origin originator history in Europe and North America and current pricing shaped by generic competition. Market performance is therefore driven less by new approvals and more by:

• Population prevalence of major depressive disorder and anxiety-related syndromes
• Generics penetration and price compression
• Formulary placement in key markets
• Switching behavior among antidepressants due to tolerability and clinician familiarity
• Real-world adherence trends

Market structure

• Competitive landscape: generic manufacturers dominate
• Differentiation: product-specific formulation attributes (dose form, release profile) and local brand/formulary positioning
• Buying logic: payer cost + discontinuation rates + tolerability profiles

Demand drivers

• Chronicity of depression treatment and need for long-term maintenance for a subset of patients
• Clinical preference patterns in specific subgroups (e.g., where sedation is acceptable or insomnia co-occurs)
• Hospital and primary care prescribing as a key channel in many countries

---

How do generics and payer dynamics shape mirtazapine revenue projections?

Mirtazapine’s revenue trajectory is governed by a generic lifecycle:

• Late-stage growth is limited once generics establish broad coverage
• Revenue growth tracks volume more than price once price floors are reached
• Country-level reimbursement rules drive the pace of decline or stability

A business-relevant framework for projections:

1. Units: linked to antidepressant patient volumes and switching within class
2. Net price: driven by tendering, generic market shares, and pharmacy reimbursement caps
3. Mix: varies by strengths (e.g., 15 mg, 30 mg, 45 mg) and dose forms

---

What are practical 2026 to 2031 market projections for mirtazapine?

Because mirtazapine is mature and off-patent in major markets, the projection most investors use is not a “high-growth” scenario; it is a range driven by unit growth (population and persistence) versus net price erosion (generic competition).

Base-case projection (directional):

• Moderate unit growth in line with antidepressant treatment rates and population aging
• Low single-digit annual net price erosion
• Net revenue trend: broadly flat to low growth globally in nominal terms once price effects are included

Downside scenario:

• Faster price erosion due to additional generic entries in high-volume markets
• Shifts toward competing low-discontinuation agents in formularies
• Tightening reimbursement criteria for older generics

Upside scenario:

• Stable-to-improving persistence due to real-world tolerability evidence
• Continued preference in insomnia-co-morbidity treatment patterns
• Competitive stability among major generic manufacturers

Actionable investment takeaway: valuation should be built around volume durability and market-share stability rather than expecting meaningful pricing tailwinds.

---

What are the key competitive threats and substitution risks?

Mirtazapine competes in-class with both older generics and newer branded or better-supported agents across different countries. Substitution risks typically come from:

• Clinician switching to SSRIs/SNRIs where weight gain and sedation are less acceptable
• Formulary preference for specific efficacy or tolerability evidence sets
• Patient adherence concerns tied to sedation or weight gain
• Emerging evidence for alternative options in special populations

Offsetting strengths in many settings:

• Clinician familiarity and entrenched prescribing pathways
• Utility where sedation is acceptable, particularly for patients with insomnia symptoms
• Broad dosing flexibility and long-established dosing regimens

---

How do clinical development strategies by manufacturers typically monetize mirtazapine today?

With limited headroom for mechanism differentiation, companies generally pursue:

• Formulation line extensions (e.g., stability, dissolution, and release profiles where permitted)
• Comorbidity-focused studies to strengthen real-world positioning
• Comparator trials against other antidepressants to support guideline or payer uptake
• Safety focus: weight gain, sedation, elderly tolerability, withdrawal effects

These programs typically aim to protect share against substitution by maintaining evidence strength where formularies and HTA decisions influence access.

---

What does this mean for R&D planning?

For R&D or portfolio decisions tied to mirtazapine-like assets, the highest probability workstreams are:

• Real-world effectiveness evidence that matches payer needs (persistence, discontinuation, tolerability)
• Tolerability optimization through formulation or dosing strategy studies
• Population-targeted studies (elderly, insomnia co-morbidity, comorbidity cohorts)

New clinical programs that do not create payer-relevant differentiation are unlikely to change market share in a generic-dominated environment.

---

Key Takeaways

• Clinical activity is present but mostly incremental: ongoing studies skew toward Phase 4 and observational evidence rather than breakthrough efficacy trials.
• Market is mature and generic-led: revenue dynamics are driven by volume durability and price erosion from competition.
• 2026 to 2031 outlook is flat-to-low growth nominally: moderate unit growth offsets low single-digit net price erosion in a typical base-case.
• Value creation comes from line extensions and real-world differentiation: trials that improve discontinuation, tolerability, and persistence are the most likely to support formulary access.
• Substitution risk remains structural: payer and clinician switching can pressure share unless evidence supports local preferred status.

---

FAQs

1. Is mirtazapine still being studied in clinical trials?
Yes. The majority of ongoing activity is consistent with Phase 4 and real-world or comparative evidence work.

2. What endpoints matter most for market access in depression therapeutics like mirtazapine?
Payer- and guideline-relevant endpoints include response/remission timing, discontinuation due to adverse events, weight gain, and sedation-related functional effects.

3. How does generic competition affect revenue projections?
Net price declines with market entry and tendering. Projections therefore assume volume stability or modest growth plus ongoing price pressure.

4. What differentiates mirtazapine in practice versus other antidepressants?
Clinical differentiation often comes from tolerability profile tradeoffs (sedation utility in certain patients versus weight gain concerns) and clinician familiarity in routine care.

5. What is the most likely source of future upside for mirtazapine?
Evidence that strengthens real-world persistence and discontinuation outcomes, plus defensible formulation or line-extension strategies that support formulary preference.

---

References

[1] National Library of Medicine. ClinicalTrials.gov (mirtazapine search results). https://clinicaltrials.gov/
[2] European Medicines Agency. Mirtazapine product information and EPAR resources. https://www.ema.europa.eu/
[3] FDA. Drug approval packages and labeling for mirtazapine (where applicable). https://www.accessdata.fda.gov/
[4] WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD information for antidepressants including mirtazapine. https://www.whocc.no/
[5] IQVIA / industry market research reports on antidepressants and generics (category-level context). https://www.iqvia.com/